CN104884081A - 免疫原性组合物 - Google Patents

免疫原性组合物 Download PDF

Info

Publication number
CN104884081A
CN104884081A CN201380063596.3A CN201380063596A CN104884081A CN 104884081 A CN104884081 A CN 104884081A CN 201380063596 A CN201380063596 A CN 201380063596A CN 104884081 A CN104884081 A CN 104884081A
Authority
CN
China
Prior art keywords
seq
toxin
immunogenic composition
immunogenic
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380063596.3A
Other languages
English (en)
Chinese (zh)
Inventor
D.布特里奥
S.M.J.V.格迈因
H.瓦莱马克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority to CN202011473000.5A priority Critical patent/CN112807422A/zh
Publication of CN104884081A publication Critical patent/CN104884081A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201380063596.3A 2012-12-05 2013-12-03 免疫原性组合物 Pending CN104884081A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011473000.5A CN112807422A (zh) 2012-12-05 2013-12-03 免疫原性组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1221875.6 2012-12-05
GB201221875 2012-12-05
PCT/EP2013/075405 WO2014086787A1 (en) 2012-12-05 2013-12-03 Immunogenic composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202011473000.5A Division CN112807422A (zh) 2012-12-05 2013-12-03 免疫原性组合物

Publications (1)

Publication Number Publication Date
CN104884081A true CN104884081A (zh) 2015-09-02

Family

ID=49724573

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380063596.3A Pending CN104884081A (zh) 2012-12-05 2013-12-03 免疫原性组合物
CN202011473000.5A Pending CN112807422A (zh) 2012-12-05 2013-12-03 免疫原性组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202011473000.5A Pending CN112807422A (zh) 2012-12-05 2013-12-03 免疫原性组合物

Country Status (22)

Country Link
US (2) US9694064B2 (enExample)
EP (2) EP2928489B1 (enExample)
JP (2) JP6290918B2 (enExample)
CN (2) CN104884081A (enExample)
AR (1) AR093712A1 (enExample)
AU (1) AU2013354186A1 (enExample)
BR (1) BR112015012841B1 (enExample)
CA (1) CA2893435C (enExample)
CY (1) CY1121560T1 (enExample)
DK (2) DK2928489T3 (enExample)
ES (2) ES2721930T3 (enExample)
FI (1) FI3513806T3 (enExample)
HR (2) HRP20190711T1 (enExample)
HU (2) HUE061273T2 (enExample)
LT (2) LT3513806T (enExample)
PL (2) PL3513806T3 (enExample)
PT (2) PT3513806T (enExample)
SG (1) SG11201503861UA (enExample)
SI (2) SI3513806T1 (enExample)
TR (1) TR201905272T4 (enExample)
WO (1) WO2014086787A1 (enExample)
ZA (1) ZA201503927B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107397956A (zh) * 2017-08-08 2017-11-28 南开大学 一种铜绿假单胞菌外膜蛋白疫苗的制备方法及应用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE045482T2 (hu) * 2005-06-27 2019-12-30 Glaxosmithkline Biologicals Sa Immunogén készítmény
KR101907434B1 (ko) 2010-09-03 2018-10-12 발네바 오스트리아 게엠베하 C. 디피실의 a 독소 및 b 독소 단백질의 분리된 폴리펩타이드 및 이의 용도
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
EP2928489B1 (en) * 2012-12-05 2019-02-27 GlaxoSmithKline Biologicals S.A. Immunogenic composition
BE1022949B1 (fr) * 2014-06-25 2016-10-21 Glaxosmithkline Biologicals S.A. Composition immunogene
CN106659799B (zh) * 2014-07-25 2020-07-17 碧奥辛斯有限责任公司 用于制备针对因肠致病性细菌引起的感染的广谱疫苗的包含表达内置的多个表位的分子构建体的基本单元的糖缀合物疫苗
CA2976976C (en) 2015-02-19 2023-02-28 Immune Biosolutions Inc. Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CA3014498A1 (en) 2016-03-21 2017-09-28 Children's Medical Center Corporation Compositions and methods for inhibiting wnt signaling
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN110691609B (zh) * 2017-03-15 2024-04-19 诺瓦瓦克斯股份有限公司 用于诱导针对艰难梭菌的免疫应答的方法和组合物
CN112512556A (zh) 2018-01-16 2021-03-16 儿童医学中心公司 用于抑制wnt信号传导的组合物和方法
GB201804092D0 (en) * 2018-03-14 2018-04-25 Imperial Innovations Ltd Methods and compositions
US10933126B2 (en) 2018-05-03 2021-03-02 The Board Of Regents Of The University Of Oklahoma Clostridium difficile immunogenic compositions and methods of use
CA3141165A1 (en) * 2019-05-21 2020-11-26 The Regents Of The University Of California Vaccine compositions for clostridium difficile
WO2021255690A2 (en) * 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
AU2023393199A1 (en) * 2022-12-13 2025-05-29 Pfizer Inc. Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
EP4658302A1 (en) 2023-02-02 2025-12-10 GlaxoSmithKline Biologicals S.A. Immunogenic composition

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007068907A2 (en) * 2005-12-13 2007-06-21 Glaxosmithkline Biologicals Sa Vaccine compositions comprising a saponin adjuvant
WO2008043774A1 (en) * 2006-10-12 2008-04-17 Glaxosmithkline Biologicals S.A. Vaccine comprising an oil in water emulsion adjuvant
CN101330924A (zh) * 2005-12-13 2008-12-24 葛兰素史密丝克莱恩生物有限公司 包含皂苷佐剂的疫苗组合物
WO2010017383A1 (en) * 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
CN102099052A (zh) * 2008-04-16 2011-06-15 葛兰素史密丝克莱恩生物有限公司 疫苗
WO2012028741A1 (en) * 2010-09-03 2012-03-08 Intercell Ag Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
WO1988009797A1 (en) 1987-06-05 1988-12-15 The United States Of America, As Represented By Th Autocrine motility factors in cancer diagnosis and management
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ATE115862T1 (de) 1989-02-04 1995-01-15 Akzo Nobel Nv Tocole als impfstoffadjuvans.
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
KR100310510B1 (ko) 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JP2002514886A (ja) 1994-10-24 2002-05-21 プロメガ コーポレーション クロストリジウム・ディフィシル疾患の治療及び予防のためのワクチン及び抗トキシン
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP2305303A3 (en) 1997-10-20 2013-11-13 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
US6733760B1 (en) * 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
EP1169456B1 (en) 1999-04-09 2012-07-11 Intercell USA, Inc. Recombinant production of Clostridium difficile Toxin A or Toxin B
AU2001251013A1 (en) 2000-03-28 2001-10-08 Diadexus, Inc. Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer
US20090028903A1 (en) * 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
GB0711858D0 (en) 2007-06-19 2007-07-25 Glaxosmithkline Biolog Sa Vaccine
AU2008299885C1 (en) 2007-09-14 2015-06-25 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing clostridium difficile toxoids A and B
US9290565B2 (en) * 2011-05-27 2016-03-22 Glaxosmithkline Biologicals, S.A. Immunogenic composition
EP2928489B1 (en) * 2012-12-05 2019-02-27 GlaxoSmithKline Biologicals S.A. Immunogenic composition

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007068907A2 (en) * 2005-12-13 2007-06-21 Glaxosmithkline Biologicals Sa Vaccine compositions comprising a saponin adjuvant
CN101330924A (zh) * 2005-12-13 2008-12-24 葛兰素史密丝克莱恩生物有限公司 包含皂苷佐剂的疫苗组合物
WO2008043774A1 (en) * 2006-10-12 2008-04-17 Glaxosmithkline Biologicals S.A. Vaccine comprising an oil in water emulsion adjuvant
CN102099052A (zh) * 2008-04-16 2011-06-15 葛兰素史密丝克莱恩生物有限公司 疫苗
WO2010017383A1 (en) * 2008-08-06 2010-02-11 Emergent Product Development Uk Limited Vaccines against clostridium difficile and methods of use
WO2012028741A1 (en) * 2010-09-03 2012-03-08 Intercell Ag Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GARCON NATHALIE ET AL: "Development and evaluation of AS03,and adjuvant system containing[alpha]-tocopherol and squalene in an oil-in-water emulsion", 《EXPERT REVIEW OF VACCINES》 *
GINAMARIE FOGLIA ET AL: "Clostridium difficile:development of a novel candidate vaccine", 《VACCINE》 *
H.WANG ET AL: "A chimeric toxin vaccine protects against primary and recurrent clostridium difficile infection", 《INFECTION AND IMMUNITY》 *
SANDRA MOREL ET AL: "Adjuvant system AS03 containing-tocopherol modulates innate immune response and leads to improved adaptive immunity", 《VACCINE》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107397956A (zh) * 2017-08-08 2017-11-28 南开大学 一种铜绿假单胞菌外膜蛋白疫苗的制备方法及应用

Also Published As

Publication number Publication date
TR201905272T4 (tr) 2019-05-21
PL3513806T3 (pl) 2023-05-15
SI2928489T1 (sl) 2019-05-31
BR112015012841B1 (pt) 2022-05-03
SI3513806T1 (sl) 2023-04-28
SG11201503861UA (en) 2015-06-29
CA2893435A1 (en) 2014-06-12
EP2928489A1 (en) 2015-10-14
JP6626521B2 (ja) 2019-12-25
EP3513806A1 (en) 2019-07-24
DK2928489T3 (en) 2019-04-23
AU2013354186A1 (en) 2014-06-12
PT2928489T (pt) 2019-05-28
DK3513806T3 (da) 2023-02-27
HUE061273T2 (hu) 2023-06-28
US10130694B2 (en) 2018-11-20
JP2016502551A (ja) 2016-01-28
LT3513806T (lt) 2023-04-11
EP3513806B1 (en) 2023-01-25
US9694064B2 (en) 2017-07-04
WO2014086787A1 (en) 2014-06-12
ES2939307T3 (es) 2023-04-20
ZA201503927B (en) 2017-11-29
AR093712A1 (es) 2015-06-17
EP2928489B1 (en) 2019-02-27
CN112807422A (zh) 2021-05-18
DK3513806T5 (da) 2024-09-02
JP2018104446A (ja) 2018-07-05
US20170340719A1 (en) 2017-11-30
CA2893435C (en) 2024-11-12
PT3513806T (pt) 2023-03-02
PL2928489T3 (pl) 2019-07-31
HRP20190711T1 (hr) 2019-05-31
ES2721930T3 (es) 2019-08-06
HUE043091T2 (hu) 2019-08-28
BR112015012841A2 (pt) 2017-09-26
HRP20230359T1 (hr) 2023-06-09
FI3513806T3 (fi) 2023-04-26
JP6290918B2 (ja) 2018-03-07
US20150313984A1 (en) 2015-11-05
CY1121560T1 (el) 2020-05-29
LT2928489T (lt) 2019-04-10

Similar Documents

Publication Publication Date Title
JP6626521B2 (ja) 免疫原性組成物
US10377816B2 (en) Nucleotide sequences, vectors and host cells
CN105120892B (zh) 包含艰难梭菌cdtb和/或cdta蛋白的元件的免疫原性组合物
JP2021035950A (ja) 変異体ブドウ球菌抗原
JP2015528457A (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対する免疫化のための安定化されたタンパク質
Lu et al. Systemic and mucosal immune responses elicited by intranasal immunization with a pneumococcal bacterium-like particle-based vaccine displaying pneumolysin mutant Plym2
US8916162B2 (en) Botulinum neurotoxin antigenic compositions and methods
CN106536544A (zh) 艰难梭菌免疫原性组合物
Gebara et al. Adjuvant and immunogenic activities of the 73 kDa N-terminal α-domain of BrkA autotransporter and Cpn60/60 kDa chaperonin of Bordetella pertussis
JP2015532594A (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対する免疫化のための安定化されたタンパク質

Legal Events

Date Code Title Description
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150902